Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma

BACKGROUND: Leiomyosarcoma (LMS) are 15% of adult sarcomas and remain seldom curable in metastatic phase. The TAM receptors and their ligands are overexpressed or activated in multiple malignancies, including LMS. METHODS: The TAM receptor and ligand expression was evaluated in LMS cell lines and 35...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Br J Cancer
Egile Nagusiak: Dantas-Barbosa, Carmela, Lesluyes, Tom, Loarer, François Le, Chibon, Fréderic, Treilleux, Isabelle, Coindre, Jean-Michel, Meeus, Pierre, Brahmi, Mehdi, Bally, Olivia, Ray-Coquard, Isabelle, Sunyach, Marie-Pierre, Cesne, Axel Le, Mir, Olivier, Bonvalot, Sylvie, Toulmonde, Maud, Italiano, Antoine, Saintigny, Pierre, Jean-Denis, Myriam, Ducimetiere, Francoise, Ranchere, Dominique, El Sayadi, Hiba, Alberti, Laurent, Blay, Jean-Yves
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2017
Gaiak:
Translational Therapeutics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5729471/
https://ncbi.nlm.nih.gov/pubmed/29024938
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.354
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak